Shin Jinho, Lee Chang Hwa
Division of Cardiology, Department of Internal Medicine, Hanyang University Medical Center, Seoul, Republic of Korea.
Division of Nephrology, Department of Internal Medicine, Hanyang University Medical Center, Seoul, Republic of Korea.
Kidney Res Clin Pract. 2021 Dec;40(4):542-554. doi: 10.23876/j.krcp.21.800. Epub 2021 Nov 17.
Chronic kidney disease (CKD) is associated with increased risk of cardiovascular (CV) events, and the disease burden is rising rapidly. An important contributor to CV events and CKD progression is high blood pressure (BP). The main mechanisms of hypertension in early and advanced CKD are renin-angiotensin system activation and volume overload, respectively. Sodium retention is well known as a factor for high BP in CKD. However, a BP increase in response to total body sodium or volume overload can be limited by neurohormonal modulation. Recent clinical trial data favoring intensive BP lowering in CKD imply that the balance between volume and neurohormonal control could be revisited with respect to the safety and efficacy of strict volume control when using antihypertensive medications. In hemodialysis patients, the role of more liberal use of antihypertensive medications with the concept of functional dry weight for intensive BP control must be studied.
慢性肾脏病(CKD)与心血管(CV)事件风险增加相关,且疾病负担正在迅速上升。心血管事件和CKD进展的一个重要促成因素是高血压(BP)。早期和晚期CKD中高血压的主要机制分别是肾素 - 血管紧张素系统激活和容量超负荷。钠潴留是CKD中高血压的一个众所周知的因素。然而,对全身钠或容量超负荷的血压升高可受到神经激素调节的限制。近期支持在CKD中强化降压的临床试验数据表明,在使用抗高血压药物时,就严格容量控制的安全性和有效性而言,容量与神经激素控制之间的平衡可能需要重新审视。在血液透析患者中,必须研究更自由地使用抗高血压药物并结合功能性干体重概念以强化血压控制的作用。